Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Netwo
January 31 2013 - 7:30AM
Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced
today that new clinical data on taliglucerase alfa will be
presented at the 9th Annual Meeting of the Lysosomal Disease
Network: WORLD Symposium 2013 being held February 13-15 in Orlando,
Florida.
Gregory Pastores, M.D., Associate Professor of Neurology and
Pediatrics and Director of the Neurogenetics Laboratory at The New
York University School of Medicine and study investigator will
deliver an oral presentation titled: "Plant Cell–Expressed
Recombinant Glucocerebrosidase: Taliglucerase Alfa as Therapy for
Gaucher Disease in Adults Patients Previously Treated with
Imiglucerase: 24-Month Results," on Friday, February 15, 2013 at
11:00 AM ET. These results will also be presented during the
poster sessions, which will take place on Wednesday, February 13
from 4:30-6:30 PM ET and on Thursday, February 14 from 4:30-6:00 PM
ET.
Additionally, Professor Ari Zimran, M.D., Director of the
Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel, and
study investigator will present two posters on taliglucerase alfa
during the poster sessions. The titles are as follows:
- "Long-Term Safety and Efficacy Data of Taliglucerase Alfa, a
Plant Cell–Expressed Recombinant Glucocerebrosidase, in the
Treatment of Naïve Gaucher Disease Patients: 36-Month
Results."
- "A Multicenter, Double-Blind, Randomized Safety and Efficacy
Study of Two Dose Levels of Taliglucerase Alfa in Pediatric
Patients with Gaucher Disease."
About Protalix BioTherapeutics,
Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell based
expression system, ProCellEx®. Protalix's unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner. Protalix's
first approved product manufactured by ProCellEx, ELELYSO™
(taliglucerase alfa), an enzyme replacement therapy for the
treatment of Gaucher disease, was approved for marketing by the
U.S. Food and Drug Administration in May 2012, and by Israel's
Ministry of Health in September 2012. Additional marketing
applications for taliglucerase alfa have been filed in other
countries. Protalix is partnered with Pfizer Inc. for
worldwide development and commercialization, excluding Israel,
where Protalix retains full rights. Protalix's development
pipeline also includes the following product candidates: PRX-102, a
modified version of the recombinant human alpha-GAL-A protein for
the treatment of Fabry disease; PRX-105, a pegylated recombinant
human acetylcholinesterase in development for several therapeutic
and prophylactic indications, a biodefense program and an
organophosphate-based pesticide treatment program; an
orally-delivered glucocerebrosidase enzyme that is naturally
encased in carrot cells, also for the treatment of Gaucher disease;
pr-antiTNF, a similar plant cell version of etanercept (Enbrel®)
for the treatment of certain immune diseases such as rheumatoid
arthritis, juvenile idiopathic arthritis, ankylosing spondylitis,
psoriatic arthritis and plaque psoriasis; and others.
CONTACT: Investor Contact
Marcy Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com
Media Contact
Kari Watson
MacDougall Biomedical Communications
781-235-3060
kwatson@macbiocom.com